Entrada Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025, in a virtual-only format. During the meeting, stockholders voted on two main proposals. The first proposal was the election of three Class I director nominees to the Board of Directors. Dipal Doshi, Kush M. Parmar, M.D., Ph.D., and Mary Thistle were all elected as directors. The second proposal was the ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, which was also approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-058536), on June 11, 2025, and is solely responsible for the information contained therein.